Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

被引：11

作者：

Olszewski, Adam J. ^{[1
]}

Eradat, Herbert ^{[2
]}

Avigdor, Abraham ^{[3
,4
]}

Horowitz, Netanel A. ^{[5
]}

Babu, Sunil ^{[6
]}

Levi, Itai ^{[7
]}

McKinney, Matthew ^{[8
]}

Lee, Seung Tae ^{[9
]}

Bergua Burgues, Juan Miguel ^{[10
]}

Rodriguez Izquierdo, Antonia ^{[11
]}

Bastos-Oreiro, Mariana ^{[12
]}

Ganzel, Chezi ^{[13
,14
]}

Kim, Tae Min ^{[15
]}

Jeon, Youngwoo ^{[16
]}

Taszner, Michal ^{[17
]}

Narkhede, Mayur ^{[18
]}

Kim, Won Seog ^{[19
]}

Shin, Ho-Jin ^{[20
]}

Lavie, David ^{[21
]}

Woszczyk, Dariusz ^{[22
]}

Dunshee, Diana ^{[23
]}

Kapp, Amy V. ^{[23
]}

Zhou, Mingzhu ^{[24
]}

Batlevi, Connie Lee ^{[23
]}

Ead, Wahib ^{[23
]}

Sellam, Gila ^{[25
]}

Jurczak, Wojciech ^{[26
]}

机构：

[1] Brown Univ, Providence, RI USA

[2] Univ Calif Los Angeles, Los Angeles, CA USA

[3] Sheba Med Ctr, Ramat Gan, Israel

[4] Tel Aviv Univ, Sch Med, Tel Aviv, Israel

[5] Technion, Rambam Hlth Care Campus, Haifa, Israel

[6] Ft Wayne Med Oncol & Hematol, Ft Wayne, IN USA

[7] Soroka Univ Med Ctr, Beer Sheva, Israel

[8] Duke Canc Inst, Durham, NC USA

[9] Univ Maryland, Greenebaum Comprehens Canc Ctr, Baltimore, MD USA

[10] San Pedro Alcantara Hosp, Hematol & Hemotherapy Serv, Caceres, Spain

[11] Univ Hosp October, Madrid, Spain

[12] Hosp Gen Univ Gregorio Maranon, Madrid, Spain

[13] Shaare Zedek Med Ctr, Dept Hematol, Jerusalem, Israel

[14] Hebrew Univ Jerusalem, Fac Med, Jerusalem, Israel

[15] Seoul Natl Univ Hosp, Dept Internal Med, Seoul, South Korea

[16] Yeouido St Marys Hosp, Lymphoma & Cell Therapy Res Ctr, Seoul, South Korea

[17] Med Univ Gdansk, Univ Clin Ctr, Dept Hematol & Transplantol, Gdansk, Poland

[18] Univ Alabama Birmingham, Birmingham, AL USA

[19] Sungkyunkwan Univ, Sch Med, Seoul, South Korea

[20] Pusan Natl Univ, Pusan Natl Univ Hosp, Biochem Res Inst,Sch Med, Dept Internal Med,Div Hematol Oncol, Busan, South Korea

[21] Hadassah Med Ctr, Jerusalem, Israel

[22] Univ Opole, Prov Hosp, Opole, Poland

[23] Genentech Inc, San Francisco, CA USA

[24] F Hoffmann La Roche Ltd, Shanghai, Peoples R China

[25] F Hoffmann La Roche Ltd, Basel, Switzerland

[26] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-177588

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页数：6

共 50 条

[21] Therapeutic potential of polatuzumab vedotin for the treatment of diffuse large B-cell lymphoma
Qi, Hui
Wang, Fuyang
Han, Bingrui
Wang, Xiaomin
Qiang, Xiangnan
Zhang, Zhixiang
Gu, Qiangyang
CANCER RESEARCH, 2023, 83 (07)
[22] Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study
Bobes, Alejandro
Llorente, Laura
Pradillo, Virginia
Alonso, Aranzazu
Fernandez, Ruben
Garcia-Noblejas, Ana
Lopez de la Osa, M. Jose
Casanova, Maria
Lorente, Soraya
Iglesias, Rebeca
Estevez, Monica
De Ona, Raquel
De La Fuente, Adolfo
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S479 - S479
[23] Cost effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (Pola-R-CHP) in previously untreated diffuse large B-cell lymphoma.
Kambhampati, Swetha
Saumoy, Monica
Pak, Stacy
Budde, L. Elizabeth
Mei, Matthew Genyeh
Popplewell, Leslie
Wen, Yi-Ping
Forman, Stephen J.
Kwak, Larry W.
Rosen, Steven T.
Herrera, Alex Francisco
Thiruvengadam, Nikhil
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[24] Zanubrutinib Plus Rituximab for the Treatment of Elderly Unfit Patients with Previously Untreated Diffuse Large-B Cell Lymphoma
Bai, Jiefei
Li, Jiangtao
Feng, Ru
Qian, Long
Yin, Jingjing
Zhang, Shuai
Wang, Ting
Yang, Yazi
Zhang, Chunli
Li, Jian
Liu, Hui
BLOOD, 2022, 140 : 3748 - 3749
[25] Frontline polatuzumab vedotin for diffuse large B-cell lymphoma: A survey of clinician impressions
Major, Ajay
Cliff, Edward R. Scheffer
Ermann, Daniel A.
Durani, Urshila
Russler-Germain, David A.
EJHAEM, 2022, 3 (03): : 930 - 935
[26] Polatuzumab vedotin for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma
Malecek, Mary-Kate
Watkins, Marcus P.
Bartlett, Nancy L.
EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (07) : 831 - 839
[27] Molecular Determinants of Sensitivity to Polatuzumab-Vedotin in Diffuse Large B-Cell Lymphoma
Corcoran, Sean R.
Choi, Jaewoo
Fenner, Rachel E.
Yu, Xin
Scheich, Sebastian
Hsiao, Tony
Schevchenko, Galina
Morris, Vivian M.
Phelan, James D.
Papachristou, Evangelia K.
Kishore, Kamal
D'Santos, Clive S.
Ji, Yanlong
Pittaluga, Stefania
Wright, George
Urlaub, Henning
Pan, Kuan-Ting
Oellerich, Thomas
Muppidi, Jagan R.
Hodson, Daniel James
Staudt, Louis M.
BLOOD, 2023, 142
[28] Cost-effectiveness of polatuzumab vedotin in combination with chemoimmunotherapy (pola-R-CHP) in previously untreated diffuse large B-cell lymphoma in Germany
Kambhampati, Swetha
Shumilov, Evgenii
Saumoy, Monica
Herrera, Alex F.
Tilly, Herve
Lenz, Georg
Thiruvengadam, Nikhil R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (04) : 771 - 775
[29] Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
Rita Assi
Nohad Masri
Iman Abou Dalle
Jean El-Cheikh
Hady Ghanem
Ali Bazarbachi
Clinical Hematology International, 2021, 3 (1) : 21 - 26
[30] Mosunetuzumab with polatuzumab vedotin: Subgroup analyses in patients (pts) with primary refractory or early relapsed large B-cell lymphoma (LBCL)
Assouline, Sarit
Budde, Lihua Elizabeth
Chavez, Julio C.
Diefenbach, Catherine S.
Dorritie, Kathleen Anne
Ghosh, Nilanjan
Olszewski, Adam J.
Lossos, Izidore S.
Mehta, Amitkumar
Modi, Dipenkumar
Naik, Seema
Smith, Stephen Douglas
Makadia, Sneha
Pham, Song
Wu, Hao
Batlevi, Connie Lee
To, Iris
Wei, Michael C.
Kamdar, Manali
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)

← 1 2 3 4 5 →